论文部分内容阅读
目的观察氟达拉滨、阿糖胞昔及粒细胞集落刺激因子(FLAG方案)治疗复发及难治性急性白血病的临床疗效及安全性。方法对11例复发及难治性AL患者给予1～3个疗程FLAG方案化疗,观察其疗效及不良反应。结果难治及复发患者的完全缓解率分别为57.1%(4/7例),75.0%(3/4例)。FLAG方案治疗总有效率为72.7%(8/11例)。主要不良反应为骨髓抑制和继发感染。结论FLAG方案对于复发及难治性AL患者是一种有效的治疗选择,毒性及不良反应大多能够耐受。
Objective To observe the clinical efficacy and safety of fludarabine, dextromethorphan and granulocyte-colony stimulating factor (FLAG regimen) in the treatment of relapsed and refractory acute leukemia. Methods Eleven patients with relapsed and refractory AL were given 1 ~ 3 cycles of chemotherapy with FLAG regimen, and the curative effect and adverse reactions were observed. Results The complete remission rate of refractory and recurrent patients was 57.1% (4/7 cases) and 75.0% (3/4 cases), respectively. The total effective rate of FLAG regimen was 72.7% (8/11 cases). The main adverse reactions were myelosuppression and secondary infection. Conclusion The FLAG regimen is an effective treatment option for relapsed and refractory AL patients. Most of the toxicity and adverse reactions are tolerable.